このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

基底細胞癌(BCC)患者におけるL19IL2またはL19TNFまたはL19IL2/TNF

2026年11月5日 更新者:Philogen S.p.A.

L19IL2またはL19TNFまたはL19IL2/L19TNF病変内注射による局所進行性基底細胞癌(LaBCC)治療の有効性に関する第2相対照無作為化試験

Open label, randomized study in patients with LaBCC not eligible or refusing surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board. The primary objective of the study is to evaluate the efficacy of L19IL2 or L19TNF or L19IL2/L19TNF, the secondary objectives of this study are to evaluate efficacy, safety and pharmacokinetics of immunocytokines. A minimum of 60 patients and a maximum of 180 evaluable patients will be randomized in a 1:1:1 ratio to one of the three different treatment arms of the study and will receive intralesional injections of: (i) Monotherapy 13 Mio IU (~2.17 mg) L19IL2; or (ii) Monotherapy 0.4 mg L19TNF; or (iii) Combination of 13 Mio IU L19IL2 + 0.4 mg L19TNF, once weekly for 4 consecutive weeks. Patients will be followed for a maximum of 156 weeks after beginning of treatment.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Tumor Assessment (TA) visits will be performed at Week 8 (Day 50 from the beginning of treatment), Week 12 (Day 78), Week 16 (Day 106) and then every 8 weeks for the first year of Follow-up (FU). During second and third years of FU, TA visits will be performed every 12 Weeks. In case a response (CR, PR) or stable disease (SD) is observed, a confirmatory assessment of the tumor response will be performed 4 weeks after the TA visit, when the objective response was first recorded.

Tumor response shall be evaluated according to composite criteria, i.e. BCC-RECIST-like. Measurement of tumor lesions and documentation (photographic documentation with use of a caliper for cutaneous lesions; ultrasound for subcutaneous lesions; imaging techniques as MRI) will be performed at every TA visit.

Confirmation of response or stable disease will be assessed by histopathological analysis of specimens from the treated skin area by multiple punch biopsies. Confirmation of tumor responses will be centrally reviewed by an independent committee (Independent Central Review, ICR).

After the TA visit confirmatory of partial response or stable disease, surgery with a curative intention can be performed if considered appropriate in the judgement of the investigator and if agreed upon by the patient; in these cases, pathological response in the exeresis specimen(s) will be evaluated as described above.

Patients will be followed for overall survival (OS) after a relapse or progression, and any further treatment given will be recorded for three years. Phone contact or any other documented contact with the patient will be recorded every 6 months for OS assessment from treatment start until the death of the patient, withdrawal of consent or until study completion (LPLV).

L19IL2 or L19TNF or L19IL2/L19TNF will be administered to eligible patients under the supervision of the investigator or identified sub-investigator(s). Patients will receive intratumoral administrations of immunocytokines into injectable cutaneous, and subcutaneous tumors once weekly for up to 4 weeks.

On the day of each treatment visit, all tumors to be injected should be measured and recorded (using caliper/ruler for cutaneous lesions and/or ultrasound for subcutaneous lesions). The recommended volume to be injected into the tumor(s) is dependent on the size of the lesion(s). The maximum dose to be administered in a single treatment visit is:

i) 13 MioIU L19IL2, or ii) 0.4 mg L19TNF or iii) 13 MioIU L19IL2 + 0.4 mg L19TNF It is recommended that each lesion should receive the maximum amount possible to inject due to tumor properties at each visit.

研究の種類

介入

入学 (推定)

180

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Florida
      • Tampa、Florida、アメリカ、33612
        • 募集
        • H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.
        • 主任研究者:
          • Jonathan S Zager, MD
    • Georgia
      • Atlanta、Georgia、アメリカ、30322
        • 募集
        • Winship Cancer Institute, Emory University
        • 主任研究者:
          • Michael C. Lowe, MD
    • North Carolina
      • Durham、North Carolina、アメリカ、27710
        • 募集
        • Duke University Medical Center
        • 主任研究者:
          • Melodi J Whitley, MD
    • Ohio
      • Cleveland、Ohio、アメリカ、44106
        • まだ募集していません
        • University Hospitals Cleveland Medical Center
        • 主任研究者:
          • Luke D. Rothermel, MD
      • Columbus、Ohio、アメリカ、43210
        • まだ募集していません
        • The Ohio State University Wexner Medical Center Clinical Laboratories
        • 主任研究者:
          • Carlo Contreras, MD
    • Texas
      • Houston、Texas、アメリカ、77030
        • 募集
        • The University of Texas MD Anderson Cancer Center
        • 主任研究者:
          • Michael R Migden, MD
      • Naples、イタリア、80131
        • 募集
        • IRCCS Istituto Nazionale Tumori Fondazione Pascale
        • 主任研究者:
          • Paolo Ascierto, Prof.
      • Roma、イタリア、00168
        • 募集
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
        • 主任研究者:
          • Ketty Peris, Prof.
      • Rozzano、イタリア、20089
        • 募集
        • Humanitas Mirasole S.p.A.
        • 主任研究者:
          • Paolo Bossi, Prof.
      • Siena、イタリア、53100
        • 募集
        • Azienda Ospedaliero-Universitaria Senese
        • 主任研究者:
          • Annamaria Di Giacomo, Prof.
      • Athens、ギリシャ、16121
        • まだ募集していません
        • Andreas Syngros Hospital Of Venereal And Dermatological Diseases
        • 主任研究者:
          • Alexandros Stratigos, Prof.
      • Barcelona、スペイン、08036
        • 募集
        • Hospital Clinic De Barcelona
        • 主任研究者:
          • Agustin Toll Abello, Prof.
      • Augsburg、ドイツ、86179
        • 募集
        • Universitaetsklinikum Augsburg
        • 主任研究者:
          • Julia Welzel, Prof.
      • Berlin、ドイツ、10117
        • 募集
        • Charite Universitaetsmedizin Berlin KöR
        • 主任研究者:
          • Thomas Eigentler, Prof.
      • Essen、ドイツ、45147
        • 募集
        • Universitaetsklinikum Essen AöR
        • 主任研究者:
          • Dirk Schadendorf, Prof.
      • Halle、ドイツ、06120
        • 募集
        • Universitaetsklinikum Halle (Saale) AöR
        • 主任研究者:
          • Johannes Wohlrab
      • Kiel、ドイツ、24105
        • 募集
        • Universitaetsklinikum Schleswig-Holstein AöR
        • 主任研究者:
          • Katharina Kahler
      • Tübingen、ドイツ、72076
        • 募集
        • Universitaetsklinikum Tuebingen AöR
        • 主任研究者:
          • Lukas Flatz, Prof.

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Patients with high risk, locally advanced histologically confirmed (non-metastatic, node negative, single or multifocal), BCC and amenable to intratumoral injection, not eligible or refusing surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board.

  • Patients with at least one injectable and measurable cutaneous or subcutaneous lesion.

  • Patients must not have received prior HHIs and checkpoint inhibitors systemic treatment.

  • Patients may have received prior surgery and/or radiation therapy.

  • Radiotherapy must have been previously administered for their locally advanced BCC, unless radiotherapy is contraindicated or inappropriate (e.g., hypersensitivity to radiation due to genetic syndrome such as Gorlin syndrome, limitations because of location of tumor, or cumulative prior radiotherapy dose). For patients whose locally advanced BCC has been irradiated, disease must have progressed after radiation.

  • Patients must have a histologically confirmed disease that is considered to be inoperable or medical contraindication to surgery or radiotherapy, in the opinion of a Mohs dermatologic surgeon, head and neck surgeon, plastic surgeon or surgical/medical oncologist. Acceptable medical contraindications to surgery include:

    • BCC that has recurred in the same location after two or more surgical procedures and curative resection is deemed unlikely;
    • Anticipated substantial morbidity and/or deformity from surgery (e.g., removal of all or part of a facial structure, such as nose, ear, eyelid, eye; or requirement for limb amputation);
    • Medical conditions predisposing to poor surgical outcome (e.g., diabetes with history of poor wound healing);
    • Other conditions considered to be medically contraindicating must be discussed with the Medical Monitor before enrolling the patient.
  • Prior radiotherapy to the target lesions must be completed at least 4 weeks prior to first study drug administration, with all acute RT-related toxicities resolved to ≤ Grade 1.

  • Male or female patients, who are capable of giving consent, age ≥ 18 years.

  • ECOG Performance Status/WHO Performance Status ≤ 1.

  • Hemoglobin > 10.0 g/dL.

  • Platelets > 100 x 109/L.

  • ALT and AST, GGT and Lipase ≤ 1.5 x the upper limit of normal (ULN).

  • All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v. 5.0) Grade ≤ 1 unless otherwise specified.

  • Women of childbearing potential (WOCBP) must have negative pregnancy test results at screening. WOCBP must be using, from screening to three months following the last study drug administration, highly effective contraception methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion, vasectomized partner.

  • Male patients with WOCBP partners must agree to use simultaneously two acceptable methods of contraception (i.e. spermicidal gel plus condom) from the screening to three months following the last study drug administration.

  • Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion Criteria:

  • Presence of concomitant malignancies, with the exception of any cancer curatively treated more than 3 years prior to study entry and of tumors with a negligible risk for metastasis or death, such as adequately treated squamous-cell carcinoma of the skin (surgically removed 4 weeks prior to study entry), ductal carcinoma in situ of the breast, or carcinoma in situ of the cervix, early-stage asymptomatic CLL and not under active treatment (Rai 0, Binet A) will be eligible for the study.
  • Current topical or systemic chemotherapy, targeted therapy immunotherapy.
  • Patients with node positive BCC who are candidates for checkpoint inhibitor therapy.
  • Chronically impaired renal function as indicated by creatinine clearance < 60 mL/min/1.73m2 or for patients older than 65 years without albuminuria or proteinuria, creatinine clearance < 45 mL/min/1.73m2.
  • Presence of active severe bacterial or viral infections or other severe concurrent disease/infection requiring therapy, including positive tests for human immunodeficiency virus (HIV)-1 or HIV-2 serum antibody, hepatitis B virus (HBV), or hepatitis C virus (HCV). For HBV serology, the determination of HBsAg and anti-HBcAg Ab is required. In patients with serology documenting previous exposure to HBV, negative serum HBV-DNA is required. For HCV, HCV-RNA or HCV antibody test is required. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no current infection are eligible.
  • History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris, inadequately treated cardiac arrhythmias and heart insufficiency (any grade, New York Heart Association (NYHA) criteria).
  • Any abnormalities observed during baseline ECG investigations that are considered clinically significant by the investigator.
  • Known arterial aneurysms.
  • INR > 3.
  • Uncontrolled hypertension.
  • Known uncontrolled coagulopathy or bleeding disorder.
  • Known hepatic cirrhosis or severe pre-existing hepatic impairment.
  • Moderate to severe respiratory failure.
  • Active autoimmune disease that has required systemic treatment in past 2 years.
  • Patients have a diagnosis of immunodeficiency or are receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug. Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions and asthma/COPD is not considered an exclusion criterion.
  • Known history of allergy to IL2, TNF, or other human proteins/peptides/antibodies.
  • Pregnancy or breast-feeding.
  • Ischemic peripheral vascular disease (Grade IIb-IV).
  • Severe diabetic retinopathy.
  • Recovery from major trauma including surgery within 4 weeks prior to enrollment.
  • Solid organ transplant recipient or patient with iatrogenic or pathologic severe immune suppression.
  • Patients with a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
  • Patients who have received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.
  • Any conditions that in the opinion of the investigator could hamper compliance with the study protocol.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:L19IL2

Patient will receive intralesional injections of monotherapy 13 Mio IU (~2.17 mg) L19IL2. Frequency and duration are identical for all arms.

Intratumoral injections

実験的:L19IL2/L19TNF

Patient will receive intralesional injections of Combination of 13 Mio IU L19IL2 + 0.4 mg L19TNF. Frequency and duration are identical for all arms.

Intratumoral injections

実験的:L19TNF

Patient will receive intralesional injections of monotherapy 0.4 mg L19TNF. Frequency and duration are identical for all arms.

Intratumoral injections

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Best Overall Response Rate
時間枠:from enrollment to week 16

Confirmed Best Overall Response Rate per BCC-RECIST-like criteria according to ICR by Week 16.

from enrollment to week 16

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年9月28日

一次修了 (推定)

2031年2月1日

研究の完了 (推定)

2031年2月1日

試験登録日

最初に提出

2025年11月7日

QC基準を満たした最初の提出物

2025年11月7日

最初の投稿 (実際)

2025年11月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月10日

QC基準を満たした最後の更新が送信されました

2026年11月5日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • PH-L19IL2TNFCOMB-04/24
  • 2025-523229-16-00 (Ctis)
  • 2025 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。